Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.

Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.

AbbVie/Genmab’s anti-CD20 bispecific is the first subcutaneous drug in the class to win approval for FL, but despite that advantage, doctors may pick the drug they know best.

A new podcast series marking 20 years of the Scrip Awards and their recognition of biopharma sector innovation.